Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) followed by Isoniazid, Rifampicin (HR) Regimen
Treatment for HIV/AIDS - Drug-susceptible Tuberculosis
Typical Dosage: Weight-based daily or thrice-weekly dosing for Isoniazid, Rifampicin, Pyrazinamide, Ethambutol
Effectiveness
90%
Safety Score
60%
Clinical Trials
5,000
Participants
5M
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Weight-based daily or thrice-weekly dosing for Isoniazid, Rifampicin, Pyrazinamide, Ethambutol
Time to Effect
1-2 weeks for clinical improvement, 2-4 weeks for sputum conversion
Treatment Duration
6 months (2 months intensive, 4 months continuation)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
1(Treat 1 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
20(Treat 20 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$680
Monitoring:$2,300
Side Effect Mgmt:$350
Total Annual:$3,330
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$8,000/QALY
QALYs Gained
12
Outcome-Based Costs
Cost per Responder
$3,700
Cost per Remission
$3,918
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) followed by Isoniazid, Rifampicin (HR) Regimen Outcomes
for HIV/AIDS - Drug-susceptible Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Hepatotoxicity (elevated LFTs, hepatitis)
+8%
Peripheral neuropathy
+5%
Gastrointestinal upset (nausea, vomiting, abdominal pain)
+15%
Orange/red discoloration of urine/tears/sweat
+99%
Arthralgia
+15%
Optic neuritis
+3%
Rash
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov